AIRLINK 72.40 Increased By ▲ 3.20 (4.62%)
BOP 5.06 Increased By ▲ 0.16 (3.27%)
CNERGY 4.31 Increased By ▲ 0.05 (1.17%)
DFML 31.32 Increased By ▲ 0.07 (0.22%)
DGKC 80.45 Increased By ▲ 3.20 (4.14%)
FCCL 21.07 Increased By ▲ 1.07 (5.35%)
FFBL 35.35 Increased By ▲ 0.35 (1%)
FFL 9.26 Increased By ▲ 0.14 (1.54%)
GGL 9.90 Increased By ▲ 0.10 (1.02%)
HBL 112.80 Increased By ▲ 0.04 (0.04%)
HUBC 134.80 Increased By ▲ 1.76 (1.32%)
HUMNL 7.03 Increased By ▲ 0.08 (1.15%)
KEL 4.38 Increased By ▲ 0.15 (3.55%)
KOSM 4.40 Increased By ▲ 0.15 (3.53%)
MLCF 37.35 Increased By ▲ 0.75 (2.05%)
OGDC 136.70 Increased By ▲ 3.83 (2.88%)
PAEL 23.69 Increased By ▲ 1.05 (4.64%)
PIAA 24.60 Increased By ▲ 0.40 (1.65%)
PIBTL 6.55 Increased By ▲ 0.09 (1.39%)
PPL 122.01 Increased By ▲ 5.71 (4.91%)
PRL 26.40 Increased By ▲ 0.50 (1.93%)
PTC 13.30 Increased By ▲ 0.22 (1.68%)
SEARL 52.60 Increased By ▲ 0.60 (1.15%)
SNGP 71.30 Increased By ▲ 3.70 (5.47%)
SSGC 10.65 Increased By ▲ 0.11 (1.04%)
TELE 8.44 Increased By ▲ 0.16 (1.93%)
TPLP 11.10 Increased By ▲ 0.30 (2.78%)
TRG 60.75 Increased By ▲ 1.46 (2.46%)
UNITY 25.12 Decreased By ▼ -0.01 (-0.04%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,519 Increased By 109.9 (1.48%)
BR30 24,663 Increased By 627.1 (2.61%)
KSE100 71,752 Increased By 1084.9 (1.54%)
KSE30 23,512 Increased By 288.1 (1.24%)
World

EU regulator could approve Covid vaccines 'late 2020, early 2021'

  • The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech, Moderna, and Oxford University-AstraZeneca.
Published November 23, 2020

THE HAGUE: Europe's medicines regulator said Monday that it could approve the first coronavirus vaccines late this year or early next, as it evaluates the most promising candidates.

The clarification came after EU Commission president Ursula von der Leyen said last week that the watchdog could give the green light for vaccines tested by Pfizer-BioNTech and by Moderna before the end of December.

"It is difficult to predict timelines for the authorisation of vaccines precisely at this stage, as the data are still coming in and the rolling reviews are currently ongoing," the European Medicines Agency said in an emailed statement to AFP.

"Depending on how the evaluation progresses, EMA could indeed be in a position to conclude evaluation for the most advanced candidates towards the end of this year or the beginning of next."

The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech, Moderna, and Oxford University-AstraZeneca.

US giant Pfizer and Germany's BioNTech has already sent data to the EMA after the companies said clinical trials showed their experimental vaccine is 95 percent effective.

US-based Moderna meanwhile says its vaccine is 94.5 percent effective, and Oxford and AstraZeneca said Monday that theirs showed 70 percent effectiveness, rising to 90 percent depending on the type of dosage.

Several European countries have already unveiled strategies to roll out coronavirus vaccines to large parts of their populations as soon as they are approved by the EMA.

Comments

Comments are closed.